Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will present a corporate overview and participate in 1-on-1 meetings at the H.C. Wainwright Global Investment Conference from May 23-25, 2022. The presentation is scheduled for May 24 at 7:00 am EST, featuring CEO Adelene Perkins. Infinity is focused on developing eganelisib, an innovative, oral, immuno-oncology treatment aimed at reprogramming macrophages, with multiple clinical trials underway, including the pivotal MARIO-4 trial expected to begin by the end of 2022.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022.

H.C. Wainwright Global Investment Conference Presentation (hybrid)
Date: Tuesday, May 24^th, 2022
Time: 7:00 am Eastern Standard Time
Speaker: Adelene Perkins, Chief Executive Officer
Format: Company presentation and virtual 1-on-1 meetings
Webcast Registration Link.
    *a replay will be available following the presentation for 90 days

About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic in multiple clinical studies. MARIO-4 is a frontline mTNBC randomized, double-blind, pivotal trial the Company expects to initiate by the end of 2022. MARIO-3 is the first eganelisib combination study in frontline advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in frontline TNBC and in combination with Tecentriq and Avastin^® in frontline RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo^® (nivolumab) in I/O naïve urothelial cancer. MARIO-P is a clinical program to evaluate eganelisib across various solid tumor indications, which the Company expects to initiate on a rolling basis in 3Q 2022. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.
Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin^® is a registered trademark of Genentech, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005155/en/

Irina Koffler

LifeSci Advisors, LLC

646-970-4681

ikoffler@lifesciadvisors.com

Source: Infinity Pharmaceuticals, Inc.

FAQ

What is Infinity Pharmaceuticals presenting at the H.C. Wainwright Global Investment Conference?

Infinity Pharmaceuticals will present a corporate overview and participate in 1-on-1 meetings at the H.C. Wainwright Global Investment Conference.

When is Infinity Pharmaceuticals' presentation at the H.C. Wainwright Conference?

The presentation is scheduled for May 24, 2022, at 7:00 am Eastern Standard Time.

Who will be speaking for Infinity Pharmaceuticals at the conference?

CEO Adelene Perkins will be presenting for Infinity Pharmaceuticals.

What is eganelisib and its significance for Infinity Pharmaceuticals?

Eganelisib is a first-in-class oral immuno-oncology therapeutic developed by Infinity Pharmaceuticals, aimed at reprogramming macrophages.

What clinical trials is Infinity Pharmaceuticals conducting for eganelisib?

Infinity is conducting various clinical trials, including MARIO-4, MARIO-3, MARIO-275, and MARIO-P, targeting different cancer types.